NASDAQ:ZBIO Zenas BioPharma (ZBIO) Stock Price, News & Analysis $16.26 -0.45 (-2.69%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock About Zenas BioPharma Stock (NASDAQ:ZBIO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Zenas BioPharma alerts:Sign Up Key Stats Today's Range$16.17▼$16.9150-Day Range$9.14▼$17.2852-Week Range$5.83▼$26.25Volume99,604 shsAverage Volume163,277 shsMarket Capitalization$684.71 millionP/E RatioN/ADividend YieldN/APrice Target$36.67Consensus RatingBuy Company Overview Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA. Read More Zenas BioPharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks31st Percentile Overall ScoreZBIO MarketRank™: Zenas BioPharma scored higher than 31% of companies evaluated by MarketBeat, and ranked 815th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingZenas BioPharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageZenas BioPharma has received no research coverage in the past 90 days.Read more about Zenas BioPharma's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Zenas BioPharma is -4.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Zenas BioPharma is -4.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioZenas BioPharma has a P/B Ratio of 2.86. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Zenas BioPharma's valuation and earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for ZBIO. Dividend0.0 / 5Dividend StrengthWeak Dividend YieldZenas BioPharma does not currently pay a dividend.Dividend GrowthZenas BioPharma does not have a long track record of dividend growth.Read more about Zenas BioPharma's dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for ZBIO. News and Social Media2.0 / 5News Sentiment0.53 News SentimentZenas BioPharma has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.99 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Zenas BioPharma this week, compared to 10 articles on an average week.MarketBeat Follows1 people have added Zenas BioPharma to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Zenas BioPharma insiders have not sold or bought any company stock.Percentage Held by Insiders16.50% of the stock of Zenas BioPharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Zenas BioPharma's insider trading history. Receive ZBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zenas BioPharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ZBIO Stock News HeadlinesZenas BioPharma to Present at Upcoming Healthcare Investor ConferencesAugust 26 at 7:05 AM | globenewswire.comWe Think Zenas BioPharma (NASDAQ:ZBIO) Needs To Drive Business Growth CarefullyAugust 20, 2025 | finance.yahoo.comTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed professionals, retirees, and high-net-worth savers. But the wealthy aren’t just writing checks. They’re moving fast to protect capital and purchasing power using legal, IRS-compliant strategies. American Alternative Assets just released the Mar-A-Lago Accord, a free guide revealing how to reduce Q3 tax exposure and reposition wealth before it’s drained.August 28 at 2:00 AM | American Alternative (Ad)Zenas BioPharma Faces Legal and Financial Challenges Amid Securities Class Action LawsuitAugust 13, 2025 | msn.comZenas BioPharma Reports Q2 2025 Financial ResultsAugust 13, 2025 | tipranks.comZenas BioPharma expects cash to fund operations into Q4 of 2026August 12, 2025 | msn.comZenas BioPharma reports Q2 EPS ($1.25) vs ($24.23) last yearAugust 12, 2025 | msn.comZenas BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate UpdatesAugust 12, 2025 | globenewswire.comSee More Headlines ZBIO Stock Analysis - Frequently Asked Questions How have ZBIO shares performed this year? Zenas BioPharma's stock was trading at $7.90 at the beginning of the year. Since then, ZBIO shares have increased by 105.8% and is now trading at $16.26. How were Zenas BioPharma's earnings last quarter? Zenas BioPharma, Inc. (NASDAQ:ZBIO) announced its quarterly earnings results on Tuesday, August, 12th. The company reported ($1.25) EPS for the quarter, missing the consensus estimate of ($1.02) by $0.23. When did Zenas BioPharma IPO? Zenas BioPharma (ZBIO) raised $225 million in an initial public offering (IPO) on Friday, September 13th 2024. The company issued 13,235,294 shares at $17.00 per share. Who are Zenas BioPharma's major shareholders? Top institutional investors of Zenas BioPharma include Federated Hermes Inc. (4.45%), Geode Capital Management LLC (0.89%), Schroder Investment Management Group (0.37%) and Rhumbline Advisers (0.05%). How do I buy shares of Zenas BioPharma? Shares of ZBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Zenas BioPharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Zenas BioPharma investors own include AST SpaceMobile (ASTS), Tempus AI (TEM), Trade Desk (TTD), Advanced Micro Devices (AMD), Biosig Technologies (BSGM), Ford Motor (F) and Genius Sports (GENI). Company Calendar Last Earnings8/12/2025Today8/28/2025Next Earnings (Estimated)11/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryBiotechnology Current SymbolNASDAQ:ZBIO Previous SymbolNASDAQ:ZBIO CIK1953926 WebN/A Phone(857) 271-2954FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Price Target for Zenas BioPharma$36.67 High Price Target$45.00 Low Price Target$30.00 Potential Upside/Downside+122.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($3.55) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$156.99 million Net MarginsN/A Pretax Margin-1,178.42% Return on Equity-59.21% Return on Assets-50.56% Debt Debt-to-Equity RatioN/A Current Ratio5.23 Quick Ratio5.23 Sales & Book Value Annual Sales$15 million Price / Sales46.24 Cash FlowN/A Price / Cash FlowN/A Book Value$5.69 per share Price / Book2.89Miscellaneous Outstanding Shares42,110,000Free Float35,162,000Market Cap$693.55 million OptionableN/A BetaN/A Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NASDAQ:ZBIO) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredWhat Are Some Strategies to Help Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zenas BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zenas BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.